oral glp 1 weight loss GLP-1 Pill Delivers Injection-Like Results in Clinical Trials Evolv Launches With First-Ever Oral

Description

The results, despite optimistic interpretation by the sponsors, showed little if any cardiovascular benefit that could not have been a consequence of glucose lowering with some suggestion that the net effects of some agents might be harmful on vascular disease (6)

pmid:37561576 41

We do not yet have evidence that they're safe for people without obesity, diabetes, and/or cardiometabolic disease

Quick Answer: GLP-1 receptor agonists produce significant reductions in abdominal fat and waist circumference as part of generalized weight loss, though they do not selectively target belly fat

Authors identified 51,408 adults with newly diagnosed type 2 diabetes and overweight or obesity who initiated treatment with either GLP-1 RAs (25,704 users) or SGLT2 inhibitors (25,704 users) following 1:1 propensity score matching to adjust for differences at baseline